Peyronie’s Disease. Last Editorial Review: 3/23/2012.. Acknowledgments Publications made by the Clearinghouse are reviewed by both NIDDK scientists and outside specialists carefully. This publication was examined by Arnold Melman, M.D., Montefiore Medical Center, Bronx, NY, and Tom Lue, M.D., University of California at San Francisco. Erection dysfunction and Peyronie’s disease. In: Litwin MS, Saigal CS, editors. Urologic Illnesses in America. U.S. Department of Health and Human Services, Public Health Assistance, National Institutes of Wellness, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: U.S. Government Printing Office, 2007; NIH Publication No. Epidemiology of Peyronie’s disease. International Journal of Impotence Research.Longer-term monitoring of sufferers receiving tofacitinib is usually ongoing. The %ages of sufferers with adverse occasions in each MedDRA category had been similar across the active treatments, and the %ages of sufferers who reported serious adverse events, severe adverse events, and either temporary or permanent discontinuations in both tofacitinib groups were related to those in the adalimumab group. Patients from our research could continue taking tofacitinib as part of a long-term extension trial.